{
    "clinical_study": {
        "@rank": "41774", 
        "acronym": "CinBiCarn", 
        "arm_group": [
            {
                "arm_group_label": "Bicarbonate", 
                "arm_group_type": "Experimental", 
                "description": "The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate.\nIntervention: Hydration strategy using sodium bicarbonate Intervention: Coronarography"
            }, 
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Active Comparator", 
                "description": "The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution.\nIntervention: Hydration strategy using saline Intervention: Coronarography"
            }, 
            {
                "arm_group_label": "Bicar + L-Carnitine", 
                "arm_group_type": "Experimental", 
                "description": "The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.\nIntervention: Hydration strategy using sodium bicarbonate Intervention: L-carnitine Intervention: Coronarography"
            }, 
            {
                "arm_group_label": "Saline + L-carnitine", 
                "arm_group_type": "Experimental", 
                "description": "The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.\nIntervention: Hydration strategy using saline Intervention: L-carnitine Intervention: Coronarography"
            }
        ], 
        "brief_summary": {
            "textblock": "The general objective of this open, pilot study is to characterize biological parameters\n      related to acute kidney injury among patients undergoing a programmed coronarography with\n      injection of contrast material. The study focuses on two main factors that may influence\n      acute kidney injury: (1) sodium chloride hydration strategy versus sodium bicarbonate\n      hydration strategy and (2) presence of oral L-carnitine treatment versus absence of oral\n      L-carnitine treatment. We will also test for a potential interaction between these two\n      factors."
        }, 
        "brief_title": "Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Kidney Injury", 
            "Renal Insufficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Acute Kidney Injury", 
                "Renal Insufficiency", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient must have given his/her informed and signed consent\n\n          -  The patient must be insured or beneficiary of a health insurance plan\n\n          -  The patient is scheduled for a coronarography\n\n          -  The patient can come back to the hospital on days 2, 3 and 7 after the coronarography\n             for follow up\n\n          -  The patient has moderate to severe renal insufficiency (glomerular filtration rate <\n             60 ml / min / 1.73 m^2)\n\n          -  The patient has not had any oral antidiabetic treatments, or diuretic treatments,\n             within 48 hours preceding the coronarography\n\n        Exclusion Criteria:\n\n          -  The patient is participating in another study\n\n          -  The patient is in an exclusion period determined by another study\n\n          -  The patient is under judicial protection\n\n          -  The patient is under any kind of guardianship\n\n          -  The patient refuses to sign the consent form\n\n          -  It is impossible to correctly inform the patient\n\n          -  The patient is unable to participate in follow-up visits at days 2, 3 and 7 after the\n             coronarography via his/her own means and a provided transportation allowance of 50\n             euros\n\n          -  The patient is pregnant or breastfeeding\n\n          -  The patient is taking L-carnitine\n\n          -  The patient has a contra indication for a treatment used in this study\n\n          -  Acute heart failure\n\n          -  Infarction, acute phase\n\n          -  Hemodialysis patient\n\n          -  Myeloma\n\n          -  Epileptic patient treated with Depakine (valproic acid) (carnitine can lower\n             epilepsy-related thresholds by speeding up the metabolism of Depakine)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01786824", 
            "org_study_id": "LOCAL/2012/PR-03", 
            "secondary_id": "2012-004134-42"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Saline", 
                    "Saline + L-carnitine"
                ], 
                "description": "For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.", 
                "intervention_name": "Hydration strategy using saline", 
                "intervention_type": "Drug", 
                "other_name": "Sodium chloride hydration"
            }, 
            {
                "arm_group_label": [
                    "Bicarbonate", 
                    "Bicar + L-Carnitine"
                ], 
                "description": "For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.", 
                "intervention_name": "Hydration strategy using sodium bicarbonate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Bicar + L-Carnitine", 
                    "Saline + L-carnitine"
                ], 
                "description": "Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.\nFor days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed.", 
                "intervention_name": "L-carnitine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Bicarbonate", 
                    "Saline", 
                    "Bicar + L-Carnitine", 
                    "Saline + L-carnitine"
                ], 
                "description": "All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate).  The day of coronarography = Day 0.", 
                "intervention_name": "Coronarography", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Carnitine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "contrast induced nephropathy", 
            "hydration strategy", 
            "L-carnitine"
        ], 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "N\u00eemes Cedex 09", 
                        "country": "France", 
                        "state": "Gard", 
                        "zip": "30029"
                    }, 
                    "name": "CHU de N\u00eemes - H\u00f4pital Universitaire Car\u00e9meau"
                }, 
                "investigator": [
                    {
                        "last_name": "Pascal Reboul, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Patrick Messner, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Serge Lumbroso, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49933"
                    }, 
                    "name": "CHU d'Angers - H\u00f4tel-Dieu"
                }, 
                "investigator": [
                    {
                        "last_name": "Alain Furber, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jean-Fran\u00e7ois Subra, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Avignon", 
                        "country": "France", 
                        "zip": "84902"
                    }, 
                    "name": "CH d'Avignon - Centre Hospitalier Henri Duffaut"
                }, 
                "investigator": [
                    {
                        "last_name": "Marc Metge, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Patrick Donnadieu, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34295"
                    }, 
                    "name": "CHU de Montpellier - H\u00f4pital Lapeyronie"
                }, 
                "investigator": [
                    {
                        "last_name": "Florence Leclercq, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jean-Paul Christol, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Georges Mourad, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perpignan", 
                        "country": "France", 
                        "zip": "66046"
                    }, 
                    "name": "CH de Perpignan - H\u00f4pital Saint Jean"
                }, 
                "investigator": [
                    {
                        "last_name": "Christian Boureux, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Carlos Vela, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Preventing Nephropathy Induced by Iodinated Contrast Media in Patients With Renal Impairment: a Randomized Trial Evaluating the Effectiveness of Two Hydration Strategies and L-carnitine Administration", 
        "overall_contact": {
            "email": "pascal.reboul@chu-nimes.fr", 
            "last_name": "Pascal Reboul, MD", 
            "phone": "+33.(0)4.66.68.35.56"
        }, 
        "overall_contact_backup": {
            "email": "carey.suehs@chu-nimes.fr", 
            "last_name": "Carey M Suehs, PhD", 
            "phone": "+33.(0)4.66.68.67.88"
        }, 
        "overall_official": {
            "affiliation": "Centre Hospitalier Universitaire de N\u00eemes", 
            "last_name": "Pascal Reboul, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Committee for the Protection of Personnes", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change in MDRD glomerular filtration rate before coronarography, and 48 hours after the injection of contrast material.", 
            "measure": "Change in glomerular filtration rate", 
            "safety_issue": "Yes", 
            "time_frame": "baseline versus 48 hours after contrast injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01786824"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The presence/absence of contrast induced nephropathy, defined by the presence of at least one of the following:\na >= 25% increase in creatinemia as compared to baseline\nan absolute increase >= 44 \u00b5mol/L in creatinemia as compared to baseline\na decrease >= 25% in glomerular filtration rate as compared to baseline", 
                "measure": "Contrast induced nephropathy?", 
                "safety_issue": "Yes", 
                "time_frame": "Day 2"
            }, 
            {
                "description": "The presence/absence of contrast induced nephropathy, defined by the presence of at least one of the following:\na >= 25% increase in creatinemia as compared to baseline\nan absolute increase >= 44 \u00b5mol/L in creatinemia as compared to baseline\na decrease >= 25% in glomerular filtration rate as compared to baseline", 
                "measure": "Contrast induced nephropathy?", 
                "safety_issue": "Yes", 
                "time_frame": "Day 3"
            }, 
            {
                "description": "The presence/absence of contrast induced nephropathy, defined by the presence of at least one of the following:\na >= 25% increase in creatinemia as compared to baseline\nan absolute increase >= 44 \u00b5mol/L in creatinemia as compared to baseline\na decrease >= 25% in glomerular filtration rate as compared to baseline", 
                "measure": "Contrast induced nephropathy?", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The brute change in creatinemia between baseline and Day 2", 
                "measure": "Change in creatinemia", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 2"
            }, 
            {
                "description": "The brute change in creatinemia between baseline and Day 3", 
                "measure": "Change in creatinemia", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 3"
            }, 
            {
                "description": "The brute change in creatinemia between baseline and Day 7", 
                "measure": "Change in creatinemia", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 7"
            }, 
            {
                "description": "% change in creatinemia between baseline and Day 2", 
                "measure": "% Change in creatinemia", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 2"
            }, 
            {
                "description": "% change in creatinemia between baseline and Day 3", 
                "measure": "% Change in creatinemia", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 3"
            }, 
            {
                "description": "% change in creatinemia between baseline and Day 7", 
                "measure": "% Change in creatinemia", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 7"
            }, 
            {
                "description": "Change in glomerular filtration (MDRD; ml/min/1.73m^2) rate compared to baseline", 
                "measure": "Change in glomerular filtration rate compared to baseline", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 2"
            }, 
            {
                "description": "Change in glomerular filtration (MDRD; ml/min/1.73m^2) rate compared to baseline", 
                "measure": "Change in glomerular filtration rate compared to baseline", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 3"
            }, 
            {
                "description": "Change in glomerular filtration (MDRD; ml/min/1.73m^2) rate compared to baseline", 
                "measure": "Change in glomerular filtration rate compared to baseline", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus Day 7"
            }, 
            {
                "measure": "Quantity of contrast material injected / glomerular filtration rate", 
                "safety_issue": "No", 
                "time_frame": "Day 0 - just after coronarography"
            }, 
            {
                "measure": "Quantity of iodine injected / glomerular filtration rate", 
                "safety_issue": "No", 
                "time_frame": "Day 0, just after coronarography"
            }, 
            {
                "description": "Was hemodialysis required for the patient? yes/no", 
                "measure": "Hemodialysis necessary?", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The patient passed away during the study. yes/no", 
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "description": "The change in serum ngal (neutrophil gelatinase associated lipocalin) between baseline and 4 hours after the injection of contrast material.", 
                "measure": "Change in serum ngal", 
                "safety_issue": "Yes", 
                "time_frame": "baseline versus 4 hours after contrast injection"
            }
        ], 
        "source": "Centre Hospitalier Universitaire de N\u012bmes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de N\u012bmes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}